Altimmune, Inc. operates primarily in the biotechnology sector, specializing in the research and development of peptide-based treatments for metabolic and liver conditions. The company's pipeline is anchored by pemvidutide, an investigational GLP-1/glucagon dual receptor agonist designed to address high-need indications such as metabolic dysfunction-associated steatohepatitis (MASH) and obesity. In addition to MASH, Altimmune is advancing pemvidutide through Phase 2 clinical trials for alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). As a clinical-stage entity, Altimmune does not currently have commercialized products and generates revenue primarily through research funding, collaborations, and licensing arrangements. The company is headquartered in Gaithersburg, Maryland, and focuses entirely on advancing its clinical pipeline toward regulatory approval and potential commercialization.
